← Back to Search

Gene Therapy

Engensis for Diabetic Neuropathy (REGAiN-1A Trial)

Phase 3
Waitlist Available
Research Sponsored by Helixmith Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female participants age ≥ 18 years at time of completion of the informed consent process
If on medication for painful DPN (other than gabapentin or pregabalin), must be on a stable dose defined as < 50% change in total dose over 3 months prior to completion of informed consent process
Must not have
Do you weigh more than 180 pounds?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 days
Awards & highlights

REGAiN-1A Trial Summary

This study is evaluating whether a drug may help treat painful diabetic peripheral neuropathy.

Eligible Conditions
  • Diabetic Neuropathy

REGAiN-1A Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
were randomized to either the intervention group or the delayed intervention group Male or female participants were randomized to either the intervention group or the delayed intervention group.
Select...
If you are taking medication for DPN pain (other than gabapentin or pregabalin), your dose must be stable for the three months before you sign the consent form.
Select...
Capable of following the instructions in the protocol and willing to comply with the requirements of the protocol, including signing the consent form.
Select...
People who have type 1 or 2 diabetes mellitus and meet the following conditions: - Are on current Standards of Medical Care in Diabetes - 2020 optimal guideline-directed medical therapy - Do not have unstable diabetes or significant medical problems, such as progressive end-organ disease, within 3 months of or during Screening - Have a glycosylated hemoglobin A1c (HbA1c) of ≤ 10.0% using the first assessment collected during Screening - Are in the judgment of the Investigator will be eligible to participate in the study.
Select...
Have you been diagnosed with Type 1 or Type 2 Diabetes? test
Select...
Do you experience painful diabetic peripheral neuropathy?
Select...
Have you been diagnosed with bilateral painful DPN in both lower extremities for at least six months?

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

REGAiN-1A Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy of Engensis compared to Placebo on painful DPN in the feet and lower legs comparing the Average Daily Pain Score from the Day 0 Visit to the Day 180 Visit on the Brief Pain Inventory for Participants with Diabetic Peripheral Neuropathy
Secondary outcome measures
Foot
Efficacy of Engensis on the worst pain in painful DPN in the feet and lower legs by comparing the change from baseline (Day 0) in the Worst Pain score from the Brief Pain Inventory for Diabetic Peripheral Neuropathy to Day 180 compared to Placebo
Safety of Engensis in painful DPN in the feet and lower legs by comparing the incidence of adverse and serious adverse events, the incidence of injection site reactions, and the incidence of clinically significant laboratory values to Placebo
+2 more
Other outcome measures
To determine whether IM administration of Engensis has the potential for disease modification by measuring the improvement in Bedside Sensory Testing at Day 180 compared to Baseline
To determine whether IM administration of Engensis has the potential for improving quality of life, sensation, proprioception, and deep tendon reflexes by measuring the improvement in Bedside Sensory Testing at Day 180 compared to Baseline

REGAiN-1A Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: EngensisExperimental Treatment1 Intervention
16 (ea) 0.25mg (0.5 mL) injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
Group II: PlaceboPlacebo Group1 Intervention
16 0.5 mL injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Engensis
2021
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Helixmith Co., Ltd.Lead Sponsor
19 Previous Clinical Trials
1,481 Total Patients Enrolled
~33 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top